Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL 2: Safety of Weekly Somapacitan in Adults with GHD
NCT02382939Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2015
- Primary completion
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of somapacitan in growth hormone deficiency (GHD) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Incidence of Adverse Events at 26 weeks and Incidence of Injection Site Reactions at 26 weeks. Started Feb 2015; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT02382939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02382939.